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Background: Within B-cell lineage cell surface receptor CD150/SLAMF1 is broadly expressed starting from pre-B cells with up-
regulation toward plasma cells. However, expression of CD150 is rather limited on the surface of malignant B cells with the block 
of differentiation at the different stages of maturation. The aim of our work was to explore CD150 expression both on protein and 
mRNA levels with the emphasis on CD150 isoforms in malignant B-cell lines at the different stages of maturation in comparison with 
their normal B cell counterparts. Materials and Methods: Studies were performed on normal tonsillar B-cell subpopulations, B-
lymphoblastoid cell lines, malignant B-cell lines of different origin, including pre-B acute lymphoblastic leukemia, Burkitt’s lym-
phoma, Hodgkin’s lymphoma, and multiple myeloma. Protein CD150 expression was assessed by western blot analysis and the expres-
sion level of CD150 isoforms was evaluated using qRT-PCR. Results: Despite the similar CD150 expression both on mRNA and 
protein levels in normal B-cell subsets and B-lymphoblastoid cell lines, malignant B-cell lines demonstrated substantial heterogeneity 
in CD150 expression. Only Hodgkin’s lymphoma cell lines, Burkitt’s lymphoma cell lines BJAB and Raji, and also pre-B cell line 
BLIN-1 expressed CD150 protein. At the same time total CD150 and mCD150 mRNA was detected in all studied cell lines excluding 
pre-B cell line REH. The minor sCD150 isoform was found only in Hodgkin’s lymphoma cell lines and Burkitt’s lymphoma cell line 
Raji. The nCD150 isoform was broadly expressed in tested B cell lines with exception of REH and Daudi. Conclusion: Malignant B-
cell lines at the different stages of maturation only partially resemble their normal counterparts by CD150 expression. In malignant 
B-cell lines, CD150 expression on mRNA level is much broader than on protein level. CD150 isoforms are differentially expressed 
in normal and malignant B cells with predominant expression of mCD150 isoform.
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CD�5� �IPO�/SLAM� is m�ltif�nctional type I trans-
membrane glycoprotein that belongs to signaling lym-
phocytic activation molec�le (SLAM� family within the 
imm�noglob�lin s�perfamily of s�rface receptors [���]. 
It is expressed on activated T and B cells� activated 
monocytes� macrophages and dendritic cells [4��]. 
Within B-cell lineage there is a noticeable heterogeneity 
in CD�5� cell s�rface expression. Nearly half of B-cell 
progenitors in bone marrow �pro-B and pre-B cells� 
express CD�5� on the cell s�rface [�]. The level 
of CD�5� s�rface expression is dropped on immat�re 
B cells and increased from the stage of naïve B cells to-
ward plasma cells [����]. At the same time� expression 
of CD�5� is rather limi ted on the s�rface of malignant 
B cells with the block of differentiation at the different 
stages of mat�ration. High level of CD�5� s�rface 
expression is observed in hairy cell le�kemia� classical 
Hodgkin’s lymphoma �HL�� s�btype of diff�se large 
B-cell lymphoma with activated B cell phenotype �ABC-
DLBCL�� and primary c�taneo�s follic�lar centre B-cell 
lymphoma [�����]. Chronic lymphocytic le�kemia 
is characterized by heterogeneity of CD�5� expres-
sion with higher s�rface CD�5� expression in m�tated 
CLL s�bgro�p [�4� �5]. It sho�ld be emphasized that 
in the part of CLL cases CD�5� expression was lost 
d�ring malignant transformation [�5]. The low level 
of CD�5� expression was also observed in mantle 
cell lymphoma [��]. However� DLBCL with germinal 
centre phenotype� small lymphocytic lymphoma� lym-
phoplasmacytic lymphoma� B�rkitt’s lymphoma �BL�� 
pre-B ac�te lymphoblastic le�kemia �pre-B ALL�� and 
m�ltiple myeloma �MM� were CD�5� negative [�����]. 
The differential CD�5� cell s�rface expression in B-cell 
malignancies co�ld be explained by several mecha-
nisms: aberrant translocation of CD�5� to the plasma 
membrane� disr�ptions in reg�lation of CD�5� expres-
sion on the transcriptional and/or translational levels.
CD�5� is encoded by SLAMF1 gene that is lo-
calised on the long arm of chromosome � at bands 
�q����4 within SLAM family gene cl�ster [���]. Seve-
ral alternatively spliced isoforms of CD�5� have been 
identified [5� ��� ��] �Fig. ��. Canonical transmembrane 
CD�5� isoform �mCD�5�� with two ITSM signaling mo-
tifs in cytoplasmic domain is the most widely st�died 
isoform. All available data abo�t CD�5� mediated 
signaling is concerning mCD�5� isoform [�]. Expres-
sion of secreted CD�5� isoform �sCD�5��� which lacks 
transmembrane region� was detected in activated nor-
mal B and T cells� mat�re dendritic cells� cases of clas-
sical HL and HL cell lines� in blood ser�m of healthy 
individ�als and patients with rhe�matoid arthritis [�� 
��� �����]. Since CD�5� is a self-ligand� sCD�5� iso-
form may interact with transmembrane CD�5� in local 
microenvironment and initiate signaling pathways that 
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leads to reg�lation of CD�5�+ cells f�nction and fate. 
In addition� variable membrane CD�5� �vmCD�5�� 
isoform with tr�ncated cytoplasmic tail and cytoplas-
mic CD�5� �cCD�5�� isoform lacking leader seq�ence 
were predicted [5]. Recently� a novel spliced isoform 
of CD�5� �nCD�5�� with alternatively cytoplasmic 
tail was identified [��]. The nCD�5� is characterized 
by ��bp insert after transmembrane region. Cytoplas-
mic tail of nCD�5� lacks ITSM motifs and its signaling 
properties are still �nknown [��].
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Fig. 1. Str�ct�re of CD�5� isoforms. mCD�5� isoform — canoni-
cal transmembrane form of CD�5� with two ITSM motifs in cyto-
plasmic tail. Sol�ble or secreted form of CD�5� �sCD�5�� lacks 
transmembrane domain. Cytoplasmic CD�5� isoform �cCD�5�� 
is devoid of the leader seq�ence� and variable CD�5� isoform 
�vmVD�5�� has one ITSM motif and tr�ncated cytoplasmic tail. 
The novel CD�5� �nCD�5�� isoform d�e to the additional insert 
after transmembrane region possess the alternative cytoplasmic 
tail witho�t any known signaling motifs
The existence of alternatively spliced CD�5� iso-
forms with different signaling properties indicates 
that they may mediate m�ltiple f�nctions by dif-
ferential expression in lymphoid pop�lation at dif-
ferent stages of cell mat�ration. Up to date� there 
is no complete information abo�t differential expres-
sion of CD�5� isoforms in malignant B cells and the 
contrib�tion of different isoforms to CD�5�-mediated 
signaling. In this st�dy� we are foc�sed on eval�ation 
of general CD�5� protein level and mRNA expres-
sion levels of CD�5� splice isoforms with conven-
tional cytoplasmic tail �mCD�5��� alternatively spliced 
cytoplasmic tail �nCD�5�� and sol�ble secreted 
CD�5� �sCD�5�� in malignant B-cell lines at the dif-
ferent stages of differentiation in comparison with their 
normal B-cell co�nterparts. To assess the expression 
level of CD�5� isoforms we performed q�antitative 
reverse transcription polymerase chain reaction �qRT-
PCR� �sing primers that recognize �niq�e regions 
of CD�5� transcripts for each of isoforms. Up to now� 
qRT-PCR is the only method that allows eval�ating dif-
ferential expression of CD�5� isoforms� since all known 
antibody recognised extracell�lar part of CD�5�� which 
is identical in all CD�5� isoforms.
MATERIALS AND METHODS
Isolation of normal B cells subpopulations. 
Tonsils were obtained from patients �ndergoing tonsil-
lectomy. Monon�clear cell pop�lations were isolated 
by Lymphoprep �Axis-Shield PoCAS� Norway� density 
gradient centrif�gation. The obtained cells were then 
depleted of T cells by E-rosetting with previo�sly pre-
pared sheep red blood cells. S�bpop�lations of normal 
B cells were isolated from total tonsillar B cells �sing 
direct magnetic separation. Dynabeads coated with 
sheep anti-mo�se IgG �Dynal Biotech ASA� Norway� 
were washed twice in PBS+�% FCS and inc�bated 
either with mo�se anti-CD�� ��� µg/ml� �Imm�notech� 
France�� or anti-CD�� ��� µg/ml� �BD Biosciences 
Pharmingen� USA�� or anti-IgD ��� µg/ml� �Imm�no-
tech� France� mAb d�ring 4� min at 4 °C with rotation. 
Then� CD��-beads� CD��-beads and IgD-beads were 
washed � times with cold PBS+�% FCS and added 
to s�spension of total tonsillar B cells at concentra-
tion of fo�r beads per cell with next inc�bation d�ring 
�� min at 4 °C with rotation. Using combination of de-
pletion and positive isolation� the following s�bpop�la-
tions of tonsillar B cells were isolated: IgD+CD��−CD��− 
�naïve B cells�� CD��+CD��−IgD− �germinal centre 
B cells� — CD��+CD��−IgD− �memory B cells�.
Cell lines. The B-lymphoblastoid cell lines �B-LCL� 
T5-�� MP-�� CESS� �.��; pre-B ALL cell lines REH� 
BLIN-�� NALM�; BL B-cell lines Ramos� Raji� B�AB� 
Da�di; HL B-cell lines KM-H�� L4��� and MM сell line 
RPMI ���� were kindly provided by Prof. Edward Clark 
�University of Washington� Seattle� WA� USA�. HL cell 
line L���� from DSMZ was kindly provided by Prof. Eva 
Klein �Karolinska Instit�te� Stockholm� Sweden�. Cell 
lines were maintained in RPMI ��4� medi�m s�pple-
mented with ��% FCS� � mM L-gl�tamine and antibi-
otics at �� °C in a h�midified atmosphere containing 
5% CO�.
Biochemical methods. Cell pellets were lysed 
in Triton lysis b�ffer ��5� mM NaCl� � mM EDTA� 
� mM EGTA� �� mM Tris pH = �.�� �% Triton Х���� con-
taining cocktails of protease and phosphatase inhibi-
tors �Sigma� USA�. Lysates were s�bjected to sodi�m 
dodecyl s�lfate polyacrylamide gel electrophoresis. 
Proteins were transferred to Immobilon-NC mem-
branes �Millipore� USA� and blocked d�ring 5 h with 
5% non fat dried milk in Tris-b�ffered saline with Tween 
�� �TBS-T�. Membranes were inc�bated with primary 
anti-CD�5� rabbit antibodies �Sino Biologicals Inc.� 
China� at 4 °C overnight followed by secondary goat 
anti-rabbit HRP-conj�gated antibodies �Santa Cr�z 
Biotechnology� USA� for � h at room temperat�re. Cla-
rity Western ECL s�bstrate �Imm�nо-Star HRP� BioRad� 
USA� and medical X-ray film �AGFA� Belgi�m� were 
�sed for vis�alization of imm�noreactions.
qRT-PCR. Total RNA isolation� cDNA synthesis 
and real-time PCR were performed as described ear-
lier [��]. The following primers for real-time PCR were 
�sed: ExtrCD�5� �isoforms containing extracell�lar 
part of CD�5� receptor�: For 5՛-AGGCCCTCCAC-
GTTATCTA-�՛� Rev 5՛-GCAAAAGCGCTGAACTGA-�՛; 
Cyt-n CD�5� �isoform containing alternative cyto-
plasmic tail�: For 5՛-TGAGAAGAAGAGCCACCTT-
GA-�՛� Rev 5՛- GGTTCGTTTTACCATGGGAAG-�՛; 
Cyt-m CD�5� �isoforms containing conventional 
cytoplasmic tail�: For 5՛-GTGTATGCTGGGCTGT-
TAGG-�՛� Rev 5՛-AGAGGTAAAACGAACCATTACCA-�՛; 
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sol�ble� secreted CD�5�: For 5՛-AGACCCCTCAG-
GTAAAACG-�՛; Rev 5՛-TCTGGACTTGGGCATAG-
ATCG-�՛. As internal control gene for normalization 
was chosen TATA-box binding protein �TBP�: For 
5՛-CCACTCACAGACTCTCACAAC-�՛; Rev 5՛-CTGCG-
GTACAATCCCAGAACT-�՛. The PCR cycling condi-
tions were the following: �� min at 95 °C� 4� cycles 
of �5 s at 95 °C and 4� s at �� °C for sCD�5� and �� min 
at 95 °C� 4� cycles of �5 s at 95 °C and 4� s at �4 °C for 
ExtrCD�5�� cyto-mCD�5� and cyto-nCD�5�. Applied 
Biosystems �5�� system software was �sed for data 
analysis. Ct val�es were determined for the internal 
control �TBP� and the tested isoforms at the same 
threshold level in the exponential phase of the PCR 
amplification c�rves. The threshold cycle �CT� method 
was �sed to calc�late expression level relative to the 
endogeno�s control. Res�lts were presented in relative 
�nits �r.�.�. Dissociation c�rve analysis was performed 
after every r�n to check the specificity of the reaction. 
For all type of cells� ��5 reactions �each in triplicates� 
were r�n for each isoform with internal control and 
standard error of the mean �SEM� was calc�lated.
RESULTS AND DISCUSSION
CD�5� expression levels were mostly st�died �sing 
flow cytometry on live cells detecting its cell s�rface 
expression [4� �� �4� �5]. To eval�ate expression of all 
CD�5� isoforms on protein level we �sed western blot 
analysis. CD�5� was expressed at approximately the 
same level in tonsillar normal B-cell s�bpop�lations with 
slightly higher level in germinal centre B cells. The lo-
west level of CD�5� was detected in memory B cells 
�Fig. �� I�. B-LCL �T5-�� MP-�� �.��� and CESS� and 
HL cell lines �KM-H�� L4�� and L����� were characte-
rized by high CD�5� expression level that exceeds 
its in normal B cells �p to fo�r times �Fig. �� II� V and 
data not shown�. The germinal centre B cells are the 
develop mentally related normal lymphoid co�nterparts 
of BL B cells [��� ��]� b�t not all BL cell lines expressed 
CD�5� on the cell s�rface [4� ��� ��]. CD�5� protein 
expression was detected at the comparatively same 
level with germinal centre B cells only in B�AB and Raji 
b�t not in Ramos and Da�di BL cell lines �Fig. �� IV�. 
MM derives from plasma cells [�4] that have the highest 
level of CD�5� s�rface expression [����]. However� 
MM cell line RPMI-���� did not express CD�5� protein 
�Fig. �� VI�. Only one pre-B ALL cell line �BLIN-�� was 
CD�5� positive �Fig. �� III�� despite CD�5� expression 
was detected on the cell s�rface of nearly half of nor-
mal pre-B cells [�]. Taken together� o�r data s�ggest 
that malignant B cells are characterized by aberrant 
expression of CD�5� on protein level� in comparison 
with their normal B cell co�nterparts.
To answer the q�estion whether CD�5� is trans-
cribed in CD�5� negative B-cell lines and which of the 
CD�5� isoforms are expressed in malignant B-cell lines 
we performed qRT-PCR �sing primers that specifically 
recognize different CD�5� domains.
Primers that are specific to extracell�lar domain 
of CD�5� �extrCD�5�� allow to eval�ate the general 
mRNA expression level of all CD�5� isoforms. Primers 
to conventional cytoplasmic tail recognise the major 
transmembrane mCD�5� isoform �mCD�5�� and 
also minor cytoplasmic cCD�5� as well as tr�ncated 
vmCD�5� isoforms. Using specific primers to alterna-
tive insert in cytoplasmic tail we were able to detect 
expression of a novel nCD�5�. For the detection of se-
creted� sol�ble sCD�5� isoform we �sed primers that 
allow excl�ding the transmembrane domain.
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Fig. 2. The expression level of CD�5� protein in s�bpop�lation 
of normal tonsillar B cells �I�� B-LCL �II�� pre-B-ALL cell lines �III�� 
BL cell lines �IV�� HL cell lines �V�� MM cell line �VI�. Western blot 
analysis. Actin expression level was �sed as loading control. 
The level of CD�5� expression was normalized against the level 
of actin �sing Adobe Photoshop CS5 program and presented 
as relative �nits
CD�5� mRNA �as indicated by extCD�5�� was 
detected in all tested normal B-cell s�bsets �Fig. �� 
a�. The mCD�5� isoform was expressed at slightly 
lower level than the general CD�5� mRNA �Fig. �� 
b�. The sCD�5� mRNA expression was h�ndreds 
of times lower than general CD�5� mRNA level 
in total and germinal centre B cells. At the same time� 
sCD�5� isoform was practically �ndetectable in naïve 
and memory B-cell s�bsets �Fig. �� c�. The expression 
level of nCD�5� isoform was tenfold lesser� in compari-
son with the expression of total CD�5� or mCD�5�. 
It sho�ld be noticed that maxim�m nCD�5� mRNA 
level was detected in memory B cells �Fig. �� d�. Th�s� 
the mCD�5� transmembrane isoform with conven-
tional cytoplasmic tail is a predominant CD�5� isoform 
in s�bpop�lations of normal tonsillar B cells.
Total CD�5� �extCD�5�� mRNA was expressed 
at the highest level in B-LCL: �p to �9.�� ± �.� r.�. 
in T5-� B-LCL �Fig. 4� a I�. All B-LCLs �sed in o�r st�dy 
are Epstein — Barr vir�s �EBV� immortalized normal 
B cells with established type III EBV latency. It was previ-
o�sly shown that infection of B cells by EBV �preg�lated 
cell s�rface expression of CD�5�. Moreover� expres-
sion of CD�5� depends on EBV-encoded oncogene 
LMP� that is highly expressed in type III EBV latency 
[�5]. That is why elevated CD�5� mRNA and protein 
expression level in B-LCL� compared to normal B cells� 
co�ld be EBV-dependent. The total CD�5� �extCD�5�� 
mRNA was detected also in all tested HL cell lines and 
two BL cell lines �B�AB and Raji� that correlated with 
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CD�5� protein expression level and did not exceeded 
s�ch in normal B cells. Moreover� it was expressed at the 
low level ��p to �.� r.�.� in cell lines NALM�� Ramos� 
Da�di� and RPMI ���� �Fig. 4� a�� which did not express 
CD�5� on protein level �see Fig. ��. 
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Fig. 3. The mRNA expression level of total CD�5� isoforms 
extrCD�5� �a�� mCD�5� isoform �b�� sCD�5� isoform �c�� and 
nCD�5� �d� in total normal B cells� naïve B cells� germinal centre 
B cells and memory B cells. Real-time qRT-PCR. The res�lts� 
presented as mean of triplicates �± SEM�� are from one of three 
independent experiments
In malignant B-cell l ines expression level 
of mCD�5� transmembrane isoform with conventional 
cytoplasmic tail repeated overall expression level for total 
CD�5� �Fig. 4� b�. It was shown that sCD�5� isoform was 
expressed in all tested B-LCL� HL cell lines and BL cell 
line Raji. At the same time� sCD�5� was not fo�nd in all 
tested pre-B ALL cell lines� BL cell lines Ramos� B�AB and 
Da�di� and MM cell line RPMI ���� �Fig. 4� c� II� III� V�.
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Fig. 4. mRNA expression level of total CD�5� isoforms extrCD�5� �a�� 
mCD�5� isoform �b�� sCD�5� isoform �c�� and nCD�5� �d� in B-LCLs �I�� 
pre-B ALL cell lines �II�� BL cell lines �III�� HL cell lines �IV�� MM cell 
line �V�. Real-time qRT-PCR. The res�lts presented as mean of tripli-
cates �± SEM� are from one of three independent experiments. Red 
lines show the expression level of corresponding CD�5� isoforms 
in total tonsillar B cells
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On the other hand� the ele vated over normal B cells 
level of sCD�5� isoform was observed in �.�� and CESS 
B-LCLs �Fig. 4� d� I�. The nCD�5� mRNA was revealed 
in the majority of tested cell lines with the exception 
of pre-B ALL cell line REH and BL cell line Da�di �Fig. 4� 
d�. Similarly to normal B-cell s�bsets� in malignant B-
cell lines expression level of nCD�5� was lower� com-
pared to the expression of mCD�5� isoform �Fig. 4� d�. 
It was s�rprising that in pre-B-ALL cell line NALM-� the 
nCD�5� was a major CD�5� isoform �Fig. 4� d, II�. 
O�r res�lts demonstrated that CD�5� isoforms are 
differentially expressed in st�died B-cell lines with 
predominant expression of mCD�5� transmembrane 
splice isoform with conventional cytoplasmic tail.
9��95% of h�man lymphoma/le�kemia in ad�lts 
are of B cell origin. CD�5� is expressed at different 
stages of B cell mat�ration from pro-B to plasma cells 
with �preg�lation of its expression d�ring differentia-
tion [�� 9]. However� CD�5� cell s�rface expression is 
rather limited on malignant B cells [��� ��� ��]. In o�r 
st�dy� we revealed heterogeneity of CD�5� expres-
sion in malignant B-cell lines �s�mmarized in Table� 
that may reflect the different stages of differentiation 
of normal co�nterparts of malignant cells.
Table. Expression of CD150 on the protein and mRNA level in normal  
B-cell subsets and B-cell lines
Subpopulation 
of normal B cells 
and cell lines
Cell surface 
expression
General ex-
pression level 
(Western blot 
analysis)
mRNA expression
ex
trC
D1
50
m
CD
15
0
sC
D1
50
nC
D1
50
Naïve B cells + [9] + +++ ++ − ++
GC B cells + [9] + +++ +++ + ++
Memory B cells + [9] + ++ +++ − +++
6.16 EBV+ +++ [4] ++ +++ +++ + +
T5-1 EBV+ +++ [34] +++ +++ +++ + ++
MP-1 EBV+ +++ [34] +++ +++ +++ + +
CESS EBV+ +++ [4] ++ +++ +++ + ++
REH EBV− − [4] − − − − −
BLIN-1 EBV− ++  
(unpubl.)
+ ++ + − +
Nalm6 EBV− − [4] − ++ + − ++
Ramos EBV− − [4] − + + − +
Raji EBV+ ++ [4] + ++ + + +
BJAB EBV− ++ [4] + ++ + − +
Daudi EBV+ − [8] − + + − −
KM-H2 EBV− +++ [20, 35] ++ ++ ++ + +
L428 EBV− +++ [20, 35] ++ ++ + + +
L1236 EBV− +++ [20, 35] ++ +++ +++ + ++
RPMI 8226 EBV− − [4] − ++ ++ − +
Note: +++ high expression level; ++ medium expression level; + low expres-
sion level; — expression was not detected.
It co�ld be tr�e for pre-B-cell lines� since abo�t half 
of normal pro-B and pre-B cells express CD�5�. Only 
in one pre-B-cell line REH CD�5� was absent both 
on mRNA and protein level. In NALM� CD�5� was ex-
pressed only on mRNA level� and in BLIN-� CD�5� pro-
tein was also detected. Probably� these pre-B-cell lines 
represent their normal co�nterparts at the seq�ential 
stages of differentiation. As to BL cell lines� the sit�-
ation is different. Two of fo�r BL cell lines express 
CD�5� protein independently of EBV presence. How-
ever� all tested BL cell lines express CD�5� mRNA that 
did not exceed the level in normal B cells. At the same 
time� germinal centre B cells express CD�5� both 
on mRNA and protein level. Contrary to BL cell lines� 
in st�died HL cell lines� which derived from crippled� 
pre-apoptotic germinal centre B cells� we fo�nd the 
correlation between CD�5� expression on mRNA and 
protein levels. Despite the high level of CD�5� expres-
sion on the s�rface of normal plasma cells� MM cell 
line RPMI ���� expressed CD�5� only on mRNA 
level. Th�s� we fo�nd that in malignant B cell lines 
CD�5� expression on mRNA level is m�ch broader 
than on protein level.
95% of m�lti-exonic mammalian genes �ndergo 
alternative splicing that leads to proteomic diversi-
ties [��]. Expression of different transcript variants and 
protein isoforms often occ�rs in cell type/tiss�e spe-
cific and developmental stage specific manner [��]. 
In the past decade� it was acc�m�lated a lot of data 
abo�t altering in splicing patterns of n�mero�s genes 
�e.g. TP53, BCL2L1, TNR6, BARD1, AR, PI3K etc.� 
in cancer development and progression [��]. That 
is why� st�dying isoform expression profile is important 
for more comprehensive characterization of cancer 
heterogeneity and may reveal novel therape�tic tar-
gets. In c�rrent work� we showed that mRNA expres-
sion level of all CD�5� isoforms in malignant B-cell lines 
did not exceed that in normal B cells or even was lower. 
Up to now� signaling properties of CD�5� are associ-
ated with paired ITSM� which are present in mCD�5�� 
sCD�5� and predicted cCD�5� isoform. The primers 
that were �sed in o�r st�dy discriminate between 
sCD�5� isoform and mCD�5� + cCD�5� isoforms. The 
cCD�5� isoform d�e to the lack of leader seq�ence 
co�ld not be translocated to the endoplasmic retic�l�m 
for f�rther translation and post-translation modifica-
tions. So� cCD�5� translates into non-glycosylated 
protein core with molec�lar weight near 4� kDa. 
According to the western blot analysis of CD�5� ex-
pression� we did not observe any band in the area 
of 4��5� kDa. This fact indirectly s�ggests that 
cCD�5� is missing or expressed as a minor isoform 
in st�died normal and malignant B cells and do not 
significantly affect the res�lts obtained with primers 
to conventional cytoplasmic tail of CD�5�. Expres-
sion of sCD�5� in HL cell lines� B-LCL and BL cell line 
Raji may indicate the role of secreted CD�5� isoform 
in constit�tive activation of CD�5�-mediated signaling 
pathways. Discovery of a novel CD�5� isoform pre-
dominant expression in glial t�mors raised the q�es-
tion whether expression level of nCD�5� is higher than 
mCD�5� in cells of imm�ne system that co�ld change 
conception of CD�5� signaling properties. However� 
in o�r st�dy� increased nCD�5� expression level was 
revealed only in one st�died cell line — pre-B-cell 
line NALM�� where CD�5� protein was not detected. 
Taken together� the mCD�5� with signaling properties 
is the main CD�5� isoform in normal B-cell s�bsets� 
EBV-transformed B-LCLs and malignant B-cells lines. 
Moreover� we did not find any significant differences 
in q�antitative ratio of mRNA expression level of st�-
died CD�5� splice isoforms between malignant B-cell 
lines and normal B-cell s�btypes.
Mechanisms that �nderlie fail�re of CD�5� protein 
expression d�ring malignant transformation are c�r-
��� Experimental Oncology ��� �������� ���� ���ne�
rently �nknown. M�ltilevel reg�lation of gene expres-
sion embracing transcription� RNA processing� trans-
lation and post-translational level� allow cells strictly 
coordinate changes in profile of gene expression in re-
sponse to internal and external stim�li [�9]. The ins�f-
ficiency of CD�5� protein expression d�ring malignant 
transformation of B cells is probably associated with 
deviation at the post-transcriptional level of gene reg�-
lation. Post-transcriptional gene reg�lation incl�des 
processing of mRNA� export of mRNA to the cytoplasm 
and localization� mRNA stability and translation [��]. 
The key negative reg�lators of translation are short 
non-coding RNA — miRNAs. The miRNA can red�ce 
target gene expression via ind�ction of mRNA degrada-
tion or by inhibiting mRNA translation witho�t affecting 
of mRNA level [��]. According to the miRNAs database 
“miRTarBase” �http://mirtarbase.mbc.nct�.ed�.tw/ 
php/search.php?org=hsa&kw=SLAMF�&opt=target� 
near twenty miRNAs may potentially target CD�5�. 
However� no one p�tative miRNA for CD�5� was vali-
dated by strong experimental approaches.
Translation initiation co�ld depend on different cis-
element present in 5՛-UTR and/or �՛-UTR. Upstream 
open reading frames ��ORF� in 5՛-UTR — seq�ences 
franked by stop and start codons localised �pstream 
of the main ORF� act as major reg�lator of translation 
initiation. Approximately 5�% of h�man mRNAs contain 
�ORF. The n�mber of �ORF in mRNA correlates with 
significantly red�ced protein expression level [��]. Re-
cently� it was shown that CD�5� has at least two isoforms 
based on their 5՛-UTR str�ct�re [��]. Long isoform 
of SLAMF1 mRNA contains fo�r �ORF at 5՛-UTR and 
is characterised by 5�� times decreases its translation 
activity� in comparison with SLAMF1 mRNA short isoform 
witho�t �ORF in 5՛-UTR [��]. It is possible that in malig-
nant B-cell lines lacking expression of CD�5� protein 
transcription may switch to the long mRNA isoforms 
le ading to less efficient translation� as indicated by pre-
vailing mRNA over protein expression.
Taken together� malignant B-cell lines at the diffe-
rent stages of mat�ration only partially resemble their 
normal co�nterparts by CD�5� expression. Mostly� 
neoplastic B cells attempt to escape CD�5� protein 
expression pres�mably �sing diverse mechanisms.
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